Skip to main content
. 2016 Jul;44(7):590–595.e1. doi: 10.1016/j.exphem.2016.04.001

Figure 1.

Figure 1

Correlation between GFI136N and disease course of patients with MDS. (A) Patients from different European cohorts diagnosed with MDS on the basis of WHO criteria were genotyped with respect to the presence of GFI136N and examined with respect to median event-free survival (see also Methods); 95% confidence interval (CI) = 1.6–5.6. Median survival is indicated. (B) MDS Patients from a U.S. cohort diagnosed with MDS on the basis of WHO criteria were genotyped with respect to the presence of GFI136N and examined with respect to median event-free survival; 95% CI = 1.7–7.2. Median survival is indicated. (C) The same cohorts as in (A) were examined with respect to overall survival (death of any cause); 95% CI = 1.0–3.9. Median survival is indicated. (D) The same cohort as in (B) was examined with respect to overall survival (death from any cause) 95% CI = 1.5–5.8. Median survival is indicated. (E) Event-free survival of GFI136S homozygous patients was stratified based on IPSS classification. No sufficient follow-up was available for the International Cancer Genome Consortium (ICGC) patients. Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and Germany. Median survival is indicated. (F) Event-free survival of GFI136N homozygous or heterozygous patients was stratified based on IPSS classification. No sufficient follow up was available for the ICGC patients. Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and Germany. Median survival is indicated. (G) Event-free survival of patients (shown in A) classified as either IPSS subtype low or intermediate 1 (int-1) was stratified with respect to the presence of GFI136N; 95% CI = 1.4–6.2. (H) Patients from the U.S. and European cohorts with cytogenetic risk characteristics belonging to subtype “low” were stratified by the presence of GFI136N with respect to event-free survival; 95% CI = 1.5–5.7. Median survival is indicated. (I) Patients from the U.S. and European cohorts with cytogenetic risk characteristics belonging to subtype “intermediate” or “high” were stratified by presence of GFI136N with respect to event-free survival; 95% CI = 3.3–23.3. Median survival is indicated.